Bullock, A., Fakih, M., Gordon, M., Tsimberidou, A., El-Khoueiry, A., Wilky, B., Pimentel, A., Margolin, K., Mahadevan, D., Balmanoukian, A., Sanborn, R., Schwartz, G., Abou-Alfa, G., Bockorny, B., Moser, J., Sharma, S., Grossman, J., Rosenthal, K., O’Day, S., … Schlechter, B. (2023). LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). Annals of Oncology, 34, S178–S179. https://doi.org/10.1016/j.annonc.2023.04.014

Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A. T., Vokes, N. I., Sakhi, M., Kamesan, V., Rizvi, H., Ricciuti, B., Forde, P. M., Anagnostou, V., Riess, J. W., … Gainor, J. F. (2023). Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics, 55(5), 807–819. https://doi.org/10.1038/s41588-023-01355-5

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021

Shin, A. E., Tesfagiorgis, Y., Larsen, F., Derouet, M., Zeng, P. Y. F., Good, H. J., Zhang, L., Rubinstein, M. R., Han, Y. W., Kerfoot, S. M., Nichols, A. C., Hayakawa, Y., Howlett, C. J., Wang, T. C., & Asfaha, S. (2023). F4/80+Ly6Chigh Macrophages Lead to Cell Plasticity and Cancer Initiation in Colitis. Gastroenterology, 164(4), 593-609.e13. https://doi.org/10.1053/j.gastro.2023.01.002

Siddiqui, B. A., Chapin, B. F., Jindal, S., Duan, F., Basu, S., Yadav, S. S., Gu, A.-D., Espejo, A. B., Kinder, M., Pettaway, C. A., Ward, J. F., Tidwell, R. S. S., Troncoso, P., Corn, P. G., Logothetis, C. J., Knoblauch, R., Hutnick, N., Gottardis, M., Drake, C. G., … Subudhi, S. K. (2023). Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal for ImmunoTherapy of Cancer, 11(3), e006262. https://doi.org/10.1136/jitc-2022-006262

de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., Lee, S. Y., Bryl, M., Zer, A., Erman, M., Timcheva, C., Raja, R., Naicker, K., Scheuring, U., Walker, J., … Mok, T. (2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106–119. https://doi.org/10.1016/j.jtho.2022.09.223

Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D’Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., … Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. JAMA Oncology, 9(1), 112. https://doi.org/10.1001/jamaoncol.2022.5370

Bukhari, S., Henick, B. S., Winchester, R. J., Lerrer, S., Adam, K., Gartshteyn, Y., Maniar, R., Lin, Z., Khodadadi-Jamayran, A., Tsirigos, A., Salvatore, M. M., Lagos, G. G., Reiner, S. L., Dallos, M. C., Mathew, M., Rizvi, N. A., & Mor, A. (2023). Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Reports Medicine, 4(1), 100868. https://doi.org/10.1016/j.xcrm.2022.100868

Gartrell, R. D., Enzler, T., Kim, P. S., Fullerton, B. T., Fazlollahi, L., Chen, A. X., Minns, H. E., Perni, S., Weisberg, S. P., Rizk, E. M., Wang, S., Oh, E. J., Guo, X. V., Chiuzan, C., Manji, G. A., Bates, S. E., Chabot, J., Schrope, B., Kluger, M., … Saenger, Y. M. (2022). Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2066767

DiFranza, L. T., Chafouleas, E., Katipally, S., Stokes, M. B., Kudose, S., & Sekulic, M. (2022). Crescentic Fibrillary Glomerulonephritis in the Setting of Immune Checkpoint Inhibitor Therapy: A Report of Two Cases. Glomerular Diseases, 3(1), 69–74. Portico. https://doi.org/10.1159/000528881

Ascierto, P. A., Agarwala, S. S., Blank, C., Caracò, C., Carvajal, R. D., Ernstoff, M. S., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Grob, J.-J., Hamid, O., Krogsgaard, M., Lo, R. S., Lund, A. W., Madonna, G., Michielin, O., Neyns, B., Osman, I., … Thurin, M. (2022). Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy). Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03592-4

Galeano Niño, J. L., Wu, H., LaCourse, K. D., Kempchinsky, A. G., Baryiames, A., Barber, B., Futran, N., Houlton, J., Sather, C., Sicinska, E., Taylor, A., Minot, S. S., Johnston, C. D., & Bullman, S. (2022). Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature, 611(7937), 810–817. https://doi.org/10.1038/s41586-022-05435-0

Cohen, A. O., Woo, S.-H., Zhang, J., Cho, J., Ruiz, M. E., Gong, J., Du, R., Yarygina, O., Jafri, D. Z., Bachelor, M. A., Finlayson, M. O., Soni, R. K., Hayden, M. S., & Owens, D. M. (2022). Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2141011

Friedman, C., Carvajal, R., Davar, D., Castanon, E., Ascierto, P., Calvo, E., O’Hara, M., Powell, S., Shapira-Frommer, R., Garralda, E., Renouf, D. J., Perets, R., Yunan, M., Ravindran, P., Hammell, A., O’Brien, S., Xu, K., Wilson, N., Jhatakia, A., … Gutierrez, M. (2022). 592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results. Regular and Young Investigator Award Abstracts, A620–A621. https://doi.org/10.1136/jitc-2022-sitc2022.0592

Stein, M., Goodman, O., Dorff, T., Narayan, V., Avitia, J., McKay, R., Nordquist, L., Rettig, M., Schweizer, M., Thomas, R., Silverman, M., Yao, L., Clynes, R., & Shorr, J. (2022). 668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts, A698–A698. https://doi.org/10.1136/jitc-2022-sitc2022.0668

Liao, C.-Y., Johnson, B., Spira, A., Carbone, D., Henick, B., Overman, M., Polite, B., Roychowdhury, S., Mahipal, A., Ahn, D., Johnson, M., Schenk, D., Bae, K., Davis, M., Jooss, K., Ferguson, A., & Solomon, B. (2022). 660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen. Regular and Young Investigator Award Abstracts, A691–A691. https://doi.org/10.1136/jitc-2022-sitc2022.0660

Iwamoto, F., Tanguturi, S., Desai, A., Nayak, L., Uhlmann, E., Wang, T., Lustig, R., Hertan, L., Bagley, S., Hayden, J., Laforest-Roys, C., Muzikansky, A., McCluskey, C., Chukwueke, U., McFaline-Figueroa, J. R., Lee, E., Wen, P. Y., & Reardon, D. (2022). CTIM-18. PHASE 2 STUDY OF PD-1 BLOCKADE WITH PEMBROLIZUMAB PLUS RE-IRRADIATION FOR RECURRENT GLIOBLASTOMA (RGBM) (NCT03661723). Neuro-Oncology, 24(Supplement_7), vii63–vii64. https://doi.org/10.1093/neuonc/noac209.250

Bagley, S., Polley, M.-Y., Kotecha, R., Brem, S., Tolakanahalli, R., Iwamoto, F., Gilbert, M., Won, M., & Mehta, M. (2022). CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS. Neuro-Oncology, 24(Supplement_7), vii64–vii64. https://doi.org/10.1093/neuonc/noac209.253

Hou, J., Goodman, O., Berz, D., Yao, L., & Soni, N. (2022). 733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer. Regular and Young Investigator Award Abstracts, A765–A765. https://doi.org/10.1136/jitc-2022-sitc2022.0733

Fontana, E., Williams, A., Falchook, G., Lakhani, N., Evans, T. R. J., Gondi, V., Iwamoto, F., McKean, M., Symeonides, S., Butowski, N., McLaren, A., Henry, J., Buerki, R., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Wiegert, E., & Bexon, A. (2022). Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. European Journal of Cancer, 174, S82–S83. https://doi.org/10.1016/s0959-8049(22)01018-8

Hamid, O., Chiappori, A. A., Thompson, J. A., Doi, T., Hu-Lieskovan, S., Eskens, F. A. L. M., Ros, W., Diab, A., Spano, J.-P., Rizvi, N. A., Wasser, J. S., Angevin, E., Ott, P. A., Forgie, A., Yang, W., Guo, C., Chou, J., & El-Khoueiry, A. B. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(10), e005471. https://doi.org/10.1136/jitc-2022-005471

Perdigoto, A. L., Deng, S., Du, K. C., Kuchroo, M., Burkhardt, D. B., Tong, A., Israel, G., Robert, M. E., Weisberg, S. P., Kirkiles-Smith, N., Stamatouli, A. M., Kluger, H. M., Quandt, Z., Young, A., Yang, M.-L., Mamula, M. J., Pober, J. S., Anderson, M. S., Krishnaswamy, S., & Herold, K. C. (2022). Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes. JCI Insight, 7(17). https://doi.org/10.1172/jci.insight.156330

Vikas, P., Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022). Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice, 18(9), 649–651. https://doi.org/10.1200/op.22.00284

Lim, E., Reeves, J., Gandhi, S., Spigel, D. R., Arrowsmith, E., George, D. J., Karlix, J., Pouliot, G., Hattersley, M., Gangl, E., James, G., Thompson, J., Russell, D., Patel, B., Kumar, R., & Falchook, G. S. (2022). 1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology, 33, S1182–S1183. https://doi.org/10.1016/j.annonc.2022.07.1882

Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., … Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33(9), 968–980. https://doi.org/10.1016/j.annonc.2022.06.004

Pass, H., Kim, A. W., Felip, E., Shu, C. A., Ferris, A., Frueh, M., Gitlitz, B. J., Troutman, S., Petrek, H., Liu, X., Hsu, J., Patil, N., & Meng, R. D. (2022). 970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC. Annals of Oncology, 33, S990–S991. https://doi.org/10.1016/j.annonc.2022.07.1096

Wang, P. H., Washburn, R., Maniar, R., Mu, M., Ringham, O., Kratchmarov, R., Henick, B. S., & Reiner, S. L. (2022). Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. The Journal of Immunology, 209(4), 660–664. https://doi.org/10.4049/jimmunol.2200317

Ricciuti, B., Wang, X., Alessi, J. V., Rizvi, H., Mahadevan, N. R., Li, Y. Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N. I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V. R., Leonardi, G. C., Plodkowski, A. J., Gupta, H., Cherniack, A. D., … Awad, M. M. (2022). Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 8(8), 1160. https://doi.org/10.1001/jamaoncol.2022.1981

Palmer, C. D., Rappaport, A. R., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S.-J., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., Smith, L., Schenk, D., Skoberne, M., Taquechel, K., Marrali, M., Jaroslavsky, J. R., Nganje, C. N., Maloney, E., Zhou, R., … Jooss, K. (2022). Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nature Medicine, 28(8), 1619–1629. https://doi.org/10.1038/s41591-022-01937-6

Alvarez-Breckenridge, C., Markson, S. C., Stocking, J. H., Nayyar, N., Lastrapes, M., Strickland, M. R., Kim, A. E., de Sauvage, M., Dahal, A., Larson, J. M., Mora, J. L., Navia, A. W., Klein, R. H., Kuter, B. M., Gill, C. M., Bertalan, M., Shaw, B., Kaplan, A., Subramanian, M., … Carter, S. L. (2022). Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 10(8), 996–1012. https://doi.org/10.1158/2326-6066.cir-21-0870

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

Henick, B. S., Villarroel-Espindola, F., Datar, I., Sanmamed, M. F., Yu, J., Desai, S., Li, A., Aguirre-Ducler, A., Syrigos, K., Rimm, D. L., Chen, L., Herbst, R. S., & Schalper, K. A. (2022). Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 10(7), e005025. https://doi.org/10.1136/jitc-2022-005025

Stein, M. N., Fong, L., Tutrone, R., Mega, A., Lam, E. T., Parsi, M., Vangala, S., Gutierrez, A. A., & Haas, N. B. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist, 27(6), 453–461. https://doi.org/10.1093/oncolo/oyac048

Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., Hellmann, M. D., Hirsch, F. R., Johnson, M. L., Malik, S., Morgensztern, D., Neal, J. W., Patel, J. D., Rimm, D. L., Sagorsky, S., … Herbst, R. S. (2022). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for ImmunoTherapy of Cancer, 10(5), e003956. https://doi.org/10.1136/jitc-2021-003956

Lopci, E., Hicks, R. J., Dimitrakopoulou-Strauss, A., Dercle, L., Iravani, A., Seban, R. D., Sachpekidis, C., Humbert, O., Gheysens, O., Glaudemans, A. W. J. M., Weber, W., Wahl, R. L., Scott, A. M., Pandit-Taskar, N., & Aide, N. (2022). Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 49(7), 2323–2341. https://doi.org/10.1007/s00259-022-05780-2

Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022). Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology, 40(15), 1696–1698. https://doi.org/10.1200/jco.22.00503

Rashidi, A., Shah, C., & Sekulic, M. (2022). The Role of Kidney Biopsy in Immune Checkpoint Inhibitor-Associated AKI. Kidney360, 3(3), 530–533. https://doi.org/10.34067/kid.0000232022

Obradovic, A., Graves, D., Korrer, M., Wang, Y., Roy, S., Naveed, A., Xu, Y., Luginbuhl, A., Curry, J., Gibson, M., Idrees, K., Hurley, P., Jiang, P., Liu, X. S., Uppaluri, R., Drake, C. G., Califano, A., & Kim, Y. J. (2022). Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. Clinical Cancer Research, 28(10), 2094–2109. https://doi.org/10.1158/1078-0432.ccr-21-3570

Alhesa, A., Awad, H., Bloukh, S., Al-Balas, M., El-Sadoni, M., Qattan, D., Azab, B., & Saleh, T. (2022). PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy. International Journal of Immunopathology and Pharmacology, 36. https://doi.org/10.1177/03946320221078433

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275

Das, A., Sudhaman, S., Morgenstern, D., Coblentz, A., Chung, J., Stone, S. C., Alsafwani, N., Liu, Z. A., Karsaneh, O. A. A., Soleimani, S., Ladany, H., Chen, D., Zatzman, M., Cabric, V., Nobre, L., Bianchi, V., Edwards, M., Sambira Nahum, L. C., Ercan, A. B., … Tabori, U. (2022). Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 28(1), 125–135. https://doi.org/10.1038/s41591-021-01581-6

He, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W.-C., Tsuji, M., Pili, R., Ito, F., Ortega, J., Abrams, S. I., Ebos, J. M. L., & Lovell, J. F. (2021). Immunization with short peptide particles reveals a functional CD8+T-cell neoepitope in a murine renal carcinoma model. Journal for ImmunoTherapy of Cancer, 9(12), e003101. https://doi.org/10.1136/jitc-2021-003101

Boda, A., Ager, C., Rajapakshe, K., Lea, S., Francesco, M. E. D., Jones, P., & Curran, M. (2021). 758 High-potency synthetic STING agonists rewire the myeloid stroma in the tumour microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma. Regular and Young Investigator Award Abstracts, A793–A793. https://doi.org/10.1136/jitc-2021-sitc2021.758

Gillison, M., Awad, M., Twardowski, P., Sukari, A., Johnson, M., Lackner, R., Stein, M., DeCillis, A., Hernandez, R., Price, J., Mancini, K., Shainheit, M., Santone, G., Shukor, S., Bicak, E., Vemulapalli, V., Tjon, E., Flechtner, J., Davis, T., & Cohen, R. (2021). 485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors. Regular and Young Investigator Award Abstracts, A515–A515. https://doi.org/10.1136/jitc-2021-sitc2021.485